BIIB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.8B
+2.5%
2.7B
+10.4%
2.5B
+8.7%
2.3B
-10.1%
2.5B
Cost of Revenue
748.4M
-3.7%
776.9M
+17.5%
661.0M
+33.4%
495.5M
-26.5%
674.4M
Gross Profit
2.1B
+4.9%
2.0B
+7.8%
1.8B
+1.8%
1.8B
-4.1%
1.9B
Operating Expenses
1.9B
+6.6%
1.8B
+27.4%
1.4B
-15.8%
1.7B
+33.4%
1.3B
R&D
857.8M
+23.7%
693.6M
+21.0%
573.0M
-21.7%
731.8M
+67.0%
438.2M
SG&A
752.0M
+6.0%
709.7M
+16.9%
607.3M
-11.0%
682.5M
+14.7%
594.8M
Operating Income
128.8M
-14.6%
150.9M
-62.0%
397.4M
+303.9%
98.4M
-83.5%
597.0M
EBITDA
436.4M
-21.4%
554.9M
-9.0%
609.7M
+84.9%
329.7M
-59.1%
806.6M
Net Income
-20600000
-121.1%
97.5M
-69.5%
319.5M
+753.4%
-48900000
-110.5%
466.5M
EPS (Basic)
$-0.14
-121.2%
$0.66
-69.6%
$2.17
+757.6%
$-0.33
-110.4%
$3.18
EPS (Diluted)
$-0.14
-121.2%
$0.66
-69.3%
$2.15
+751.5%
$-0.33
-110.4%
$3.17
Shares (Diluted)
147.8M
-0.6%
148.7M
+0.2%
148.4M
+0.3%
148.0M
+0.6%
147.1M
Biogen (BIIB) — Financials